{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:44:46Z","timestamp":1753357486393,"version":"3.40.5"},"reference-count":37,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T00:00:00Z","timestamp":1647734400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Care Research and Practice"],"published-print":{"date-parts":[[2022,3,20]]},"abstract":"<jats:p>Background. Constipation is frequent in critically ill adults receiving opioids. Naloxegol (N), a peripherally acting mu-receptor antagonist (PAMORA), may reduce constipation. The objective of this trial was to evaluate the efficacy and safety of N to prevent constipation in ICU adults receiving opioids. Methods and Patients. In this single-center, double-blind, randomized trial, adults admitted to a medical ICU receiving IV opioids (\u2265100 mcg fentanyl\/day), and not having any of 17 exclusion criteria, were randomized to N (25\u2009mg) or placebo (P) daily randomized to receive N (25mg) or placebo (P) and docusate 100 mg twice daily until ICU discharge, 10 days, or diarrhea (\u22653 spontaneous bowel movement (SBM)\/24\u2009hours) or a serious adverse event related to study medication. A 4-step laxative protocol was initiated when there was no SBM \u22653\u2009days. Results. Only 318 (20.6%) of the 1542 screened adults during the 1\/17\u201310\/19 enrolment period met all inclusion criteria. Of these, only 19\/381 (4.9%) met all eligibility criteria. After 7 consent refusals, 12 patients were randomized. The study was stopped early due to enrolment futility. The N (n\u2009=\u20096) and <jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                     <\/a:math>\n                  <\/jats:inline-formula> (n\u2009=\u20096) groups were similar. The time to first SBM (N 41.4\u2009\u00b1\u200931.7 vs. P 32.5\u2009\u00b1\u200925.4 hours, <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                     <\/c:math>\n                  <\/jats:inline-formula>\u2009=\u20090.56) was similar. The maximal daily abdominal pressure was significantly lower in the N group (N 10\u2009\u00b1\u20094 vs. P 13\u2009\u00b1\u20095, <jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                     <\/e:math>\n                  <\/jats:inline-formula>\u2009=\u20090.002). The median (IQR) daily SOFA scores were higher in N (N 7 (4, 8) vs. P 4 (3, 5), <jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                     <\/g:math>\n                  <\/jats:inline-formula>\u2009&lt;\u20090.001). Laxative protocol use was similar (N 83.3% vs. P 66.6%; <jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                     <\/i:math>\n                  <\/jats:inline-formula>\u2009=\u20090.51). Diarrhea prevalence was high but similar (N 66.6% vs. <jats:inline-formula>\n                     <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mi>P<\/k:mi>\n                     <\/k:math>\n                  <\/jats:inline-formula> 66.6%; <jats:inline-formula>\n                     <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>P<\/m:mi>\n                     <\/m:math>\n                  <\/jats:inline-formula>\u2009=\u20091.0). No patient experienced opioid withdrawal. Conclusions. Important recruitment challenges exist for ICU trials evaluating the use of PAMORAs for constipation prevention. Despite being underpowered, our results suggest time to first SBM with naloxegol, if different than P, may be small. The effect of naloxegol on abdominal pressure, SOFA, and the interaction between the two requires further research.<\/jats:p>","DOI":"10.1155\/2022\/7541378","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T22:35:07Z","timestamp":1647815707000},"page":"1-10","source":"Crossref","is-referenced-by-count":2,"title":["Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial"],"prefix":"10.1155","volume":"2022","author":[{"given":"Matthew S.","family":"Duprey","sequence":"first","affiliation":[{"name":"School of Public Health, Brown University, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmony","family":"Allison","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tufts Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Garpestad","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-5726","authenticated-orcid":true,"given":"Andrew M.","family":"Riselli","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Faugno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tufts Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Anketell","sequence":"additional","affiliation":[{"name":"Department of Nursing, Tufts Medical Center, 800 Washington Street, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9012","authenticated-orcid":true,"given":"John W.","family":"Devlin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Northeastern University, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-011-2459-y"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeg275"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239061"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-006-0175-9"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/141737"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02889-4"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.014"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000002315"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.01.004"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9610(01)00782-6"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1047-x"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1310246"},{"key":"14","article-title":"Efficacy and safety of peripherally acting u-receptor anatagonts (PAMORAS) for the management of patients with opioid-induced constipation: a systematic review","volume":"16201","author":"M. Rekatsina","year":"2020","journal-title":"Cureus"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05913-6"},{"volume-title":"Movantik (Naloxegol) Package Insert","year":"2020","key":"16"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.349"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1067\/mjw.2001.119013"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.14.1754"},{"issue":"7","key":"21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00003246-199907000-00022","article-title":"Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients","volume":"27","author":"R. R Riker","year":"1997","journal-title":"Critical Care Medicine"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1007\/s001340100909"},{"key":"23","volume-title":"Procedure 106: Intraabdominal Pressure monitoring. American Association of Critical Care Nurses (AACN) Procedure Manual for Critical Care 2001","author":"D. Wiegand","year":"2017","edition":"6th"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-007-0592-4"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-018-0539-z"},{"issue":"2","key":"27","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/MCG.0000000000000316","article-title":"Prophylaxis versus treatment use of laxative for paralysis of lower gastrointestinal tract in critically ill patients","volume":"50","author":"B. Guardiola","year":"2016","journal-title":"Journal of Clinical Gastroenterology"},{"key":"28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00134-021-06418-x","article-title":"Fentanyl- and midazolam-induced coma each influence days of mechanical ventilation and 28-day mortality: a post hoc analysis of a randomized controlled analgosedation trial","volume":"47","author":"M Tanios","year":"2021","journal-title":"Intensive Care Med"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.06.008"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202010-3794oc"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2503oc"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000004896"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1097\/cce.0000000000000157"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.13872"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024922"},{"key":"36"},{"key":"37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"ACTIV-4a, and ATTACC Investigators, \u201cTherapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"The Remap-Cap","year":"2021","journal-title":"New England Journal of Medicine"}],"container-title":["Critical Care Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ccrp\/2022\/7541378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ccrp\/2022\/7541378.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ccrp\/2022\/7541378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T22:35:14Z","timestamp":1647815714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ccrp\/2022\/7541378\/"}},"subtitle":[],"editor":[{"given":"Quincy K","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,20]]},"references-count":37,"alternative-id":["7541378","7541378"],"URL":"https:\/\/doi.org\/10.1155\/2022\/7541378","relation":{},"ISSN":["2090-1313","2090-1305"],"issn-type":[{"type":"electronic","value":"2090-1313"},{"type":"print","value":"2090-1305"}],"subject":[],"published":{"date-parts":[[2022,3,20]]}}}